Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Serotonin Uptake Inhibitors | 6 | 2020 | 1425 | 0.670 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2020 | 2327 | 0.490 |
Why?
|
| Pregnancy Complications | 11 | 2019 | 2838 | 0.420 |
Why?
|
| Antidepressive Agents | 10 | 2020 | 2826 | 0.420 |
Why?
|
| Psychotropic Drugs | 4 | 2019 | 901 | 0.330 |
Why?
|
| Depression | 5 | 2016 | 7261 | 0.300 |
Why?
|
| Depression, Postpartum | 3 | 2005 | 312 | 0.270 |
Why?
|
| Psychotherapy | 3 | 2003 | 1570 | 0.260 |
Why?
|
| Bupropion | 1 | 2005 | 297 | 0.240 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2002 | 324 | 0.220 |
Why?
|
| Depressive Disorder | 7 | 2019 | 3805 | 0.220 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 511 | 0.210 |
Why?
|
| Antimanic Agents | 2 | 2019 | 530 | 0.200 |
Why?
|
| Mood Disorders | 2 | 2010 | 1102 | 0.160 |
Why?
|
| Pregnancy | 13 | 2020 | 27366 | 0.160 |
Why?
|
| Puerperal Disorders | 2 | 2000 | 281 | 0.140 |
Why?
|
| Drug Labeling | 1 | 2018 | 265 | 0.140 |
Why?
|
| Antipsychotic Agents | 3 | 2019 | 3062 | 0.130 |
Why?
|
| Reproduction | 1 | 2018 | 647 | 0.120 |
Why?
|
| Perimenopause | 1 | 2011 | 132 | 0.100 |
Why?
|
| Bipolar Disorder | 3 | 2019 | 5054 | 0.090 |
Why?
|
| Risk | 3 | 2016 | 9812 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1777 | 0.090 |
Why?
|
| Influenza A virus | 1 | 1992 | 454 | 0.090 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2019 | 621 | 0.090 |
Why?
|
| Spleen | 1 | 1992 | 2458 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1992 | 1896 | 0.070 |
Why?
|
| Estradiol | 2 | 2011 | 1982 | 0.070 |
Why?
|
| Sudden Infant Death | 1 | 2007 | 283 | 0.070 |
Why?
|
| Postpartum Period | 1 | 2010 | 985 | 0.060 |
Why?
|
| Affect | 1 | 2011 | 1491 | 0.060 |
Why?
|
| Mianserin | 1 | 2001 | 55 | 0.050 |
Why?
|
| Female | 19 | 2020 | 377052 | 0.050 |
Why?
|
| Cyclohexanols | 1 | 2001 | 129 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 1992 | 2708 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 420 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2011 | 6182 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2002 | 438 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2019 | 6445 | 0.050 |
Why?
|
| Abortion, Spontaneous | 1 | 2003 | 473 | 0.040 |
Why?
|
| Depressive Disorder, Major | 2 | 2007 | 4452 | 0.040 |
Why?
|
| Recurrence | 4 | 2006 | 8238 | 0.040 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2019 | 78 | 0.040 |
Why?
|
| Humans | 19 | 2020 | 715636 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 1983 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2002 | 755 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 2715 | 0.040 |
Why?
|
| Family Practice | 1 | 1999 | 518 | 0.040 |
Why?
|
| Lithium | 1 | 2000 | 617 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 455 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 1418 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2001 | 742 | 0.040 |
Why?
|
| Postpartum Hemorrhage | 1 | 2019 | 241 | 0.030 |
Why?
|
| Sleep | 1 | 2011 | 4187 | 0.030 |
Why?
|
| Arsenicals | 1 | 1993 | 122 | 0.030 |
Why?
|
| Nucleoproteins | 1 | 1992 | 118 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 11194 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2002 | 7445 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2005 | 8078 | 0.030 |
Why?
|
| Adult | 10 | 2011 | 212228 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1990 | 44 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1993 | 917 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1992 | 1909 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 704 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 975 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2011 | 731 | 0.020 |
Why?
|
| Hot Flashes | 1 | 2011 | 313 | 0.020 |
Why?
|
| Risk Assessment | 4 | 2010 | 23482 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1993 | 1159 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15899 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1992 | 1016 | 0.020 |
Why?
|
| Risk Factors | 4 | 2004 | 70927 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2006 | 51355 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2007 | 24779 | 0.020 |
Why?
|
| Epitopes | 1 | 1993 | 2647 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1990 | 1487 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 1886 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1992 | 1960 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2019 | 2847 | 0.020 |
Why?
|
| Parity | 1 | 2007 | 891 | 0.020 |
Why?
|
| Virus Replication | 1 | 1992 | 2565 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 1681 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1993 | 14171 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 1121 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 4182 | 0.010 |
Why?
|
| Prevalence | 1 | 1999 | 14878 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 2001 | 36 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1993 | 18601 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2006 | 587 | 0.010 |
Why?
|
| Causality | 1 | 2007 | 1180 | 0.010 |
Why?
|
| Pyridines | 1 | 2011 | 2843 | 0.010 |
Why?
|
| Cell Line | 1 | 1992 | 16574 | 0.010 |
Why?
|
| Middle Aged | 3 | 2011 | 214618 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2011 | 11948 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 85064 | 0.010 |
Why?
|
| Time Factors | 2 | 2010 | 40892 | 0.010 |
Why?
|
| Macrophages | 1 | 1990 | 5747 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2011 | 62037 | 0.010 |
Why?
|
| Menopause | 1 | 2001 | 1536 | 0.010 |
Why?
|
| Hemagglutinins, Viral | 1 | 1993 | 64 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 5034 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 3313 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1993 | 419 | 0.010 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1993 | 159 | 0.010 |
Why?
|
| Mice | 3 | 1993 | 80320 | 0.010 |
Why?
|
| United States | 1 | 2018 | 67894 | 0.010 |
Why?
|
| Mycobacterium avium | 1 | 1990 | 30 | 0.010 |
Why?
|
| Toxoplasmosis, Animal | 1 | 1990 | 18 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1993 | 651 | 0.010 |
Why?
|
| Legionella | 1 | 1990 | 32 | 0.010 |
Why?
|
| Smoking | 1 | 2007 | 8950 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2001 | 2580 | 0.010 |
Why?
|
| Arsenic | 1 | 1993 | 318 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1993 | 560 | 0.010 |
Why?
|
| Listeriosis | 1 | 1990 | 158 | 0.010 |
Why?
|
| Toxoplasma | 1 | 1990 | 156 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1990 | 146 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1993 | 1278 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2004 | 13635 | 0.010 |
Why?
|
| Chagas Disease | 1 | 1990 | 167 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1993 | 1531 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 1990 | 255 | 0.010 |
Why?
|
| Trypanosoma cruzi | 1 | 1990 | 199 | 0.010 |
Why?
|
| Male | 2 | 2018 | 350156 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2000 | 10513 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 2007 | 72439 | 0.000 |
Why?
|
| Animals | 3 | 1993 | 169277 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2007 | 40042 | 0.000 |
Why?
|
| Transfection | 1 | 1993 | 6091 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 3845 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 6633 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 13180 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 4388 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 7088 | 0.000 |
Why?
|
Concepts
(134)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(12)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_